RECELL System to be Highlighted at Upcoming Music City SCALE Multidisciplinary Dermatology Meeting

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that a discussion on the RECELL System will be held during the Symposium for Cosmetic Advances & Laser Education (SCALE) multidisciplinary dermatology meeting taking place May 11-15 in Nashville, TN. SCALE is the premier multidisciplinary meeting for aesthetic medicine, plastic surgery and medical dermatology.

The presentation will feature Dr. Jeffrey Carter, FACS, Associate Professor of Surgery and Medical Director, UMCNO Burn Center at LSU Health in New Orleans, who will discuss the use of the RECELL System for treatment of burn injuries. Additionally, Dr. Seemal Desai, FAAD, Diplomate of the American Board of Dermatology, and a Board-Certified Dermatologist, will review the clinical trial protocol aimed at establishing safety and effectiveness for repigmentation of stable vitiligo lesions utilizing the RECELL System. The discussion, “RECELL: A Novel Treatment Strategy for Regenerative & Restorative Skin Conditions” will take place Thursday, May 12 from 2:30-2:40 pm CDT.

“It is important for us to share clinical evidence and peer insights related to the RECELL System with leaders of the dermatology community to help physicians make educated treatment decisions for their patients,” said Dr. Mike Perry, Chief Executive Officer of AVITA Medical. “As we pursue the vitiligo indication, our vision is to offer the community an innovative solution to better serve the millions of people who suffer with this disease.”

Vitiligo is a disease that attacks pigment-producing cells, called melanocytes, resulting in their destruction or malfunction. The result is a loss of pigmentation in patches of skin. Vitiligo affects up to 2% of the population worldwide,ⁱ including an estimated 3-6.5 million Americans.ⁱⁱ Vitiligo has a comparable market size and psychosocial impact to other major dermatology diseases including psoriasis (thick, scaly skin) and atopic dermatitis (red, cracked skin).^iiiivv Like these diseases, those living with vitiligo may suffer from poor body image along with low self-esteem, leading to an impaired quality of life.^vi

AVITA Medical is currently completing a pivotal trial for the use of the RECELL System for treatment of stable vitiligo. Currently, the RECELL System is indicated in the U.S. for treatment of acute thermal burns. Our vitiligo clinical trial aims to demonstrate safe and effective repigmentation when using the RECELL System in combination with phototherapy. Topline data from the trial will be shared later this year.